Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in adolescents with moderate to severe plaque psoriasis
2009-014368-20Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ustekinumab in plaque psoriasis and psoriatic arthritis (PsA) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Proportion of patients achieving Physician's Global Assessment cleared or minimal. Started Mar 2010; status: completed.
02
Drugs
ustekinumab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2009-014368-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014368-20.